SOGROYA 10 mg/mL
somapacitan-beco · INJECTION, SOLUTION · Novo Nordisk
SOGROYA is a injection, solution containing somapacitan-beco at 10 mg/mL, taken subcutaneous. Manufactured by Novo Nordisk.
Key Facts
- Brand Name
- SOGROYA
- Generic Name
- somapacitan-beco
- NDC Code (Product)
0169-2037- Manufacturer
- Novo Nordisk
- Strength
- 10 mg/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761156
- Marketing Start
- 05/01/2023
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is SOGROYA used for?
SOGROYA contains somapacitan-beco. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is SOGROYA a controlled substance?
SOGROYA is not classified as a controlled substance by the DEA.
What is the generic name for SOGROYA?
The generic name for SOGROYA is somapacitan-beco. There are no other listed brand versions of somapacitan-beco.
What is the NDC code for SOGROYA 10 mg/mL?
The NDC (National Drug Code) for SOGROYA 10 mg/mL is 0169-2037, listed by Novo Nordisk.
Other SOGROYA Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)